This actually came out in September, but I just saw the article on xconomy today. Intarcia announced this fall that they had good results with an injectable slow-release pump that delivered exenatide (also called Byetta). The pump is call ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide). Looking at a total of 150 patients with type 2 diabetes, individuals were randomly chosen to receive either exenatide by injection (this is normally how Byetta is delievered) or in the implantable pump. Essentially, Intarcia showed that the pump worked as well or better than the current standard of injections. Couple of questions:
1) How big is the pump?
The pump is actually smaller than a matchstick.
2) What is the next step?
This was a phase 2 trial, so now Intarcia needs to performa a phase 3 trial. According to their website, it should open for patient recruitment in early 2011. Remember, this pump is not available to the general public – and its eventual release is dependent on the results of that phase 3 trial. As of this writing, the trial is not recruiting yet.
3) How long does the pump last?
According to their website, they’re looking at versions for 3 months, 6 months, and a full year.
In case you’re really interested, you can see the results that they showed in September here.